<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Hepatocyte nuclear factor 1-α (HNF1A)/hepatocyte nuclear factor 4-α (HNF4A) <z:hpo ids='HP_0004904'>maturity-onset diabetes of the young</z:hpo> (MODY) is frequently misdiagnosed as type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, and patients are inappropriately treated with insulin </plain></SENT>
<SENT sid="1" pm="."><plain>Blood C-<z:chebi fb="7" ids="16670">peptide</z:chebi> can aid in the diagnosis of MODY, but practical reasons limit its widespread use </plain></SENT>
<SENT sid="2" pm="."><plain>Urinary C-<z:chebi fb="7" ids="16670">peptide</z:chebi> <z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio (UCPCR), a stable measure of endogenous insulin secretion, is a noninvasive alternative </plain></SENT>
<SENT sid="3" pm="."><plain>We aimed to compare stimulated UCPCR in adults with HNF1A/4A MODY, type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: Adults with <z:mp ids='MP_0002055'>diabetes</z:mp> for ≥ 5 years, without <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e>, were studied (HNF1A MODY [n = 54], HNF4A MODY [n = 23], glucokinase MODY [n = 20], type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> [n = 69], and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> [n = 54]) </plain></SENT>
<SENT sid="5" pm="."><plain>The UCPCR was collected in <z:chebi fb="1" ids="33118">boric acid</z:chebi> 120 min after the largest meal of the day and mailed for analysis </plain></SENT>
<SENT sid="6" pm="."><plain>Receiver operating characteristic (ROC) curves were used to identify optimal UCPCR cutoffs to differentiate HNF1A/4A MODY from type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: UCPCR was lower in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> than HNF1A/4A MODY (median [interquartile range]) (&lt;0.02 nmol/mmol [&lt;0.02 to &lt;0.02] vs. 1.72 nmol/mmol [0.98-2.90]; P &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>ROC curves showed excellent discrimination (area under curve [AUC] 0.98) and identified a cutoff UCPCR of ≥ 0.2 nmol/mmol for differentiating HNF1A/4A MODY from type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> (97% sensitivity, 96% specificity) </plain></SENT>
<SENT sid="9" pm="."><plain>UCPCR was lower in HNF1A/4A MODY than in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (1.72 nmol/mmol [0.98-2.90] vs. 2.47 nmol/mmol [1.4-4.13]); P = 0.007) </plain></SENT>
<SENT sid="10" pm="."><plain>ROC curves showed a weak distinction between HNF1A/4A MODY and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (AUC 0.64) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: UCPCR is a noninvasive outpatient tool that can be used to discriminate HNF1A and HNF4A MODY from long-duration type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>To differentiate MODY from type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> of &gt;5 years' duration, UCPCR could be used to determine whether genetic testing is indicated </plain></SENT>
</text></document>